Research applications · Immuno-oncology

Tissue & data for immuno-oncology research

Study immune biomarkers in their tumor context with clinically characterized tissue microarrays and FFPE tissue samples. Select tissue by immune infiltration, treatment history and available response data, with additional assays and pathology support as needed.

Published NSCLC multiplex image showing CD68, CD8 and pan-cytokeratin
NSCLC multiplex image · AACR 2023 research poster

Immuno-oncology tissue cohorts

FFPE cohorts from checkpoint inhibitor-treated patients

Surgical resection FFPE blocks from patients treated with pembrolizumab or nivolumab, with treatment follow-up. Clinical fields vary by cohort.

Repository cohorts for immuno-oncology research
Cancer indicationDisease settingTreatment & available context
RCCPrimary RCCPembrolizumab or nivolumab; treatment follow-upInquire about this cohort →
Melanoma IO-treatedStage III/IV; metastatic samplesFirst- and second-line checkpoint inhibitor follow-upInquire about this cohort →
Melanoma Chemotherapy then IOPrimary & metastatic; stage III/IVFirst-line chemotherapy and second-line checkpoint inhibitor follow-upInquire about this cohort →
Melanoma Pre/post IO—Pre- and post-checkpoint inhibitor samples with follow-up Not donor matchedInquire about this cohort →
NSCLC—Pembrolizumab or nivolumab; treatment follow-upInquire about this cohort →
HNSCC—Pembrolizumab or nivolumab; treatment follow-upInquire about this cohort →

Biomarker-selected cohorts

Cohorts selected by recorded biomarker or treatment response

Combine the available biomarker record with treatment history and follow-up. These cohorts describe selection options; they do not establish response to immunotherapy.

Checkpoint expression

PD-L1 tissue cohorts Clone 22C3

NSCLC cohorts with PD-L1 scored by IHC across a range of expression levels.

Tell us which scoring convention your study uses — TPS, TC or CPS — and we will confirm what is recorded for the cases you need.

Discuss PD-L1 selection

HNSCC

p16 status

Recorded p16 status with clinical follow-up. p16 is not a substitute for HPV testing.

Colorectal cancer

Microsatellite instability

Colorectal cancer cohorts including MSI-H cases.

NSCLC & colorectal cancer

Treatment response

NSCLC targeted-therapy responders and non-responders; colorectal cancer standard-of-care non-responders. Ask which driver alterations and response criteria are recorded for the cases you need. These are separate from the checkpoint-inhibitor cohorts above.

Additional melanoma cohorts & cancer indications

Uveal melanoma stage II–IV, a biologically distinct disease from cutaneous melanoma, and cutaneous melanoma stage III–IV. Other repository indications include hepatocellular carcinoma, mesothelioma, cervical cancer, cholangiocarcinoma, gallbladder cancer and extrahepatic bile duct cancer.

Recorded fields vary by collection.

Sourced to your protocol

Build around your study criteria

Define your clinical and biomarker criteria and we will scope feasibility. Donor-matched pre- and on-treatment pairs are a feasibility request: specify the regimen, tissue requirements, timepoints and endpoint.

Discuss cohort feasibility

Biomarker-defined tissue

PD-L1-defined NSCLC with the clone and scoring convention specified; MMR-proficient and B7-H4-expressing endometrial cohorts; CLDN18.2-expressing gastric / GEJ cohorts.

Availability, matching and timelines are confirmed for each request.

Selected arrays

Tissue microarrays for immuno-oncology studies

Explore arrays selected for immune infiltration, immunotherapy follow-up or paired tissue comparison. Each TMA has its own tissue composition and associated data.

Counts are approximate. Product details and datasheets describe the available case-level information and assay suitability.

Browse all TMAs
Published representative cell-type maps from responder and non-responder NSCLC cases
Representative cell-type maps · TriStar / Enable Medicine, AACR 2023. View publication citation

Tissue, immune profiles & follow-up

Study immune patterns alongside treatment response

Clinically annotated specimens connect tissue findings to the donor record. Available data can include treatment regimen and line, clinician-recorded response, survival and last follow-up.

Existing molecular results and optional RNA-seq, GeoMx or IHC datasets are collection-specific. New profiling can be discussed separately for your selected tissue.

Study planning

Match the immune question to tissue and data

Start with the biological comparison, then identify the tissue regions, collection timing and available clinical records needed to interpret it.

01

Checkpoint expression and immune composition

Use selected tissue with IHC and pathology scoring to investigate checkpoint expression and immune-cell markers. Specify the relevant tumor or immune-cell compartment and scoring approach. A marker-positive tissue group and a group enriched for immune infiltration answer different questions.

02

Spatial relationships

Tumor-center and invasive-margin cores can support comparisons between defined regions. When the question concerns where immune populations sit within tissue, discuss whole sections, image analysis or spatial profiling. Agree on the regions to evaluate and the level of cellular detail required before selecting an assay.

03

Treatment and response context

Distinguish treatment-naïve tissue linked to later immunotherapy outcomes from tissue collected during or after treatment. For longitudinal comparisons, confirm donor matching and collection timing. Request the available regimen, line of therapy, recorded response and follow-up fields, alongside the assay outputs required. Associations in these cohorts do not by themselves establish a predictive biomarker of treatment benefit.

Planning expression-frequency comparisons? See biomarker prevalence studies. For tumor-target and T-cell context together, explore bispecific research.

Assays & pathology support

Add assays around your study question

Select protein, RNA or multiplex measurements to complement your tissue cohort and available donor data.

Protein expression

IHC assay services

Characterize immune checkpoints and immune-cell markers in your selected tissue, with pathology review and study-specific scoring.

Explore IHC services

Spatial RNA expression

RNAscope RNA-ISH

Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.

Explore RNAscope

Multiplex protein imaging

Multiplex immunofluorescence

Distinguish immune cell phenotypes and examine their spatial relationships with tumor cells using multiplex immunofluorescence.

Explore multiplex IF

Spatial protein data

NSCLC cohort with standard-of-care chemotherapy follow-up, available with an optional GeoMx protein panel.

100+ optimized IHC assaysVentana & Dako staining platformsPathologist review & scoring

Research & references

Research using TriStar tissue and data

Explore the research library

Organizations are identified from author affiliations, patent records and report credits. Their inclusion does not imply a partnership with or endorsement of TriStar.

Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.

Our approach begins with our customers’ science.

We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.

Scientist working with a pipette in a laboratory

Plan your study

Discuss your immuno-oncology study

Tell us your cancer indication, immune biomarkers, treatment context and required follow-up. We’ll review suitable TMAs, FFPE cohorts and any assays or pathology support you would like to add.

Discuss your study